[GIP and GLP-1: multiplicity of regulator mechanisms for insulin secretion].
Thorens
B
B
Institut de Pharmacologie et Toxicologie, Lausanne, Suisse.
D000818:Animals; D002454:Cell Differentiation; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D005749:Gastric Inhibitory Polypeptide / Q000502:physiology*; D005786:Gene Expression Regulation; D005934:Glucagon / Q000502:physiology* / Q000627:therapeutic use; D052216:Glucagon-Like Peptide 1; D000067757:Glucagon-Like Peptide-1 Receptor; D005947:Glucose / Q000494:pharmacology; D006801:Humans; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000502:physiology; D051379:Mice; D018345:Mice, Knockout; D010446:Peptide Fragments / Q000502:physiology* / Q000627:therapeutic use; D011498:Protein Precursors / Q000502:physiology* / Q000627:therapeutic use; D011964:Receptors, Gastrointestinal Hormone / Q000172:deficiency / Q000502:physiology; D018027:Receptors, Glucagon / Q000172:deficiency / Q000502:physiology; D015398:Signal Transduction
C000593833:GLP1R protein, human; C000593834:Glp1r protein, mouse; D000067757:Glucagon-Like Peptide-1 Receptor; D007328:Insulin; D010446:Peptide Fragments; D011498:Protein Precursors; D011964:Receptors, Gastrointestinal Hormone; D018027:Receptors, Glucagon; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; C041086:gastric inhibitory polypeptide receptor; D005947:Glucose